Schistosomiasis is a common parasitic disease, affecting millions of people, mostly in tropical, developing countries [
1]. A causative agent of the disease is a trematode worm,
Schistosoma mansoni. Treatment of schistosomiasis is commonly accomplished with praziquantel, for which the mechanism of action is not precisely defined but is thought to affect calcium ion channels [
2] and/or purine nucleotide uptake [
3]. Despite the effectiveness of treatment, reinfection is common, and even more troubling, strains of
S. mansoni resistant to praziquantel have been found [
4]. Thus, additional chemotherapeutic agents and an effective vaccine against this parasite have long been desired [
5].
Ideally, vaccination of at-risk populations against the debilitating effects of schistosomiasis is desired, but no such treatment option is currently available. Surface receptors and other proteins are currently being tested for their potential to act as vaccines, but numerous challenges in the search for an effective vaccine have yet to be overcome [
6]. Some candidate vaccines are effective agents but cannot be mass produced. Most other candidate proteins have little potential as a vaccine, providing only 40-50% protection [
6]. While the search for an effective vaccine continues, it is critical to continue to identify molecular targets and their potential for chemotherapeutic disruption.
Proteases have been under scrutiny as targets of immunological or chemotherapeutic anti-
Schistosoma agents because of their vital role in many stages of the parasitic life cycle [
7,
8]. In addition, proteases are known to act as important regulatory elements in a variety of species [
9,
10]. They also play a vital role as effectors of virulence in pathogens in general, often serving to alter host signal transduction and modify the immune response [
11-
14]. By targeting proteases specific to parasitic life style or those with significant dissimilarity to homologous proteases in the host species, investigators hope to find anti-schistosomal chemotherapies with minimal side effects to the host. However, few proteolytic enzymes have been purified in
Schistosoma, and even fewer have well characterized functions and interactions.
Proteases of all five catalytic classes have been identified from
Schistosoma species through proteomic or genetic analysis. Function has been established for only a handful of identified
S. mansoni proteases, and the vast majority of these are the digestive proteases involved in metabolic food processing or host tissue penetration [
15-
18]. Additional proteases that are involved in reproduction, evasion of host immune system, and development have also been characterized [
7,
19]. Very few proteases have been evaluated for the potential to serve as chemotherapeutic targets against schistosomiasis (e.g. [
20]). Fortunately, it is almost certain that additional proteases exist in the
S. mansoni genome, as the conserved classes of many regulatory proteases have not been identified from
Schistosoma species. Since current therapies for a wide variety of disorders and diseases target regulatory molecules, such proteases may serve as new and effective targets for anti-helminthic treatments. The challenge of developing new therapies involves several steps, the first of which is to identify and characterize potential targets of drug or vaccine treatments. This is currently a task that is increasingly accomplished and streamlined with genomic and bioinformatic tools [
9,
21].
The sequencing and annotation of the
S. mansoni genome [
22], combined with large EST libraries, provide a wealth of data from which to identify new vaccine or therapy targets [
23-
25]. These data, combined with bioinformatics tools and specialized databases, can fast-track the identification of potential anti-trematode agents by complementing and supplementing traditional genetic and proteomic identification techniques. Therefore, as an initial step in characterizing some of these potential targets, we survey the
S. mansoni genome and EST library for protease genes. In doing so, we identify for the first time, numerous potentially important proteases in trematodes, many of which will have essential functions and may serve as targets of effective chemotherapeutic or immunological treatments.